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Review
The endocannabinoid system: ‘NO’ longer
anonymous in the control of nitrergic signalling?
Christopher Lipina and Harinder S. Hundal*
Division of Cell Signalling and Immunology, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
* Correspondence to: Harinder S. Hundal, E-mail: h.s.hundal@dundee.ac.uk
The endocannabinoid system (ECS) is a key cellular signalling system that has been implicated in the regulation of diverse cellular
functions. Importantly, growing evidence suggests that the biological actions of the ECS may, in part, be mediated through its ability
to regulate the production and/or release of nitric oxide, a ubiquitous bioactive molecule, which functions as a versatile signalling
intermediate. Herein, we review and discuss evidence pertaining to ECS-mediated regulation of nitric oxide production, as well as
the involvement of reactive nitrogen species in regulating ECS-induced signal transduction by highlighting emerging work support-
ing nitrergic modulation of ECS function. Importantly, the studies outlined reveal that interactions between the ECS and nitrergic sig-
nalling systems can be both stimulatory and inhibitory in nature, depending on cellular context. Moreover, such crosstalk may act
to maintain proper cell function, whereas abnormalities in either system can undermine cellular homoeostasis and contribute to vari-
ous pathologies associated with their dysregulation. Consequently, future studies targeting these signalling systems may provide
new insights into the potential role of the ECS–nitric oxide signalling axis in disease development and/or lead to the identification
of novel therapeutic targets for the treatment of nitrosative stress-related neurological, cardiovascular, and metabolic disorders.
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Introduction
Nitric oxide (NO•) is a bioactive free radical produced by most
cell types, which can serve either as a beneficial physiologic
messenger or as a toxic intermediate involved in disease pro-
gression (Schmidt and Walter, 1994). Indeed, since its discovery
as a key endogenous signalling molecule in mammalian cells,
the chemical biology of NO• and its impact upon cellular func-
tion has been an important research topic for several decades.
It is now widely recognized that many of its biological actions
are mediated through its ability to regulate various signalling
pathways and/or by altering protein function through post-
translational modifications (McDonald and Murad, 1996; Azad
et al., 2006; Campanella et al., 2016; Seneviratne et al., 2016).
As a consequence of these biological actions, elevated or
reduced NO• bioavailability has been implicated in the aetiology
of a number of pathological events including the development
of various neurodegenerative, metabolic, cardiovascular, and
inflammatory disorders (Figure 1A) (Heales et al., 1999; Duncan
and Heales, 2005; Pacher et al., 2007). Consequently, there is
growing interest in identifying cellular pathways and/or processes
that can regulate the levels of NO• and other derived reactive
nitrogen species (RNS). Herein, we discuss evidence that sup-
ports a role for the endocannabinoid system (ECS), whose activity
is determined by endogenous bioactive lipids, in the regulation of
nitrergic signalling and highlight emerging evidence pertaining to
the involvement of RNS in the modulation of ECS function.
NO• synthesis in biological systems
The endogenous production of NO• is mainly driven by the
two-step oxidation of L-arginine, which can be catalyzed by
one of three isoforms of nitric oxide synthase (NOS), namely the
neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) iso-
types (Knowles et al., 1989; Boucher et al., 1999; Alderton
et al., 2001) (Figure 1B). Notably, nNOS and eNOS are constitu-
tive enzymes that require calcium and calmodulin for their acti-
vation (Busse and Mulsch, 1990; Abu-Soud et al., 1994; Salerno
et al., 1997; Forstermann and Sessa, 2012). In contrast, iNOS
activation largely involves its transcriptional upregulation in
response to pro-inflammatory stimuli (Figure 1B), which may be
important in situations where the rapid production of a large
flux of NO• is necessary, for example in stimulated immune cells
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(Xie et al., 1994; Forstermann and Sessa, 2012). Furthermore,
phosphorylation constitutes an additional mechanism for regulat-
ing NOS activity, whereby the catalytic activity of the nNOS
enzyme has been shown to decrease following its phosphoryl-
ation by cyclic adenosine monophosphate (cAMP)-dependent
protein kinase (Brune and Lapetina, 1991; Bredt et al., 1992),
protein kinase C (Nakane et al., 1991; Bredt et al., 1992), or Ca2
+/calmodulin-dependent protein kinase II (CAMKII) (Nakane et al.,
1991; Bredt et al., 1992; Komeima et al., 2000).
It is important to highlight that NO• can also be produced via
the reduction of the inorganic nitrate (NO3
–) and nitrite (NO2
–)
anions, which assimilate as end-products of the classic L-arginine–
NOS pathway following rapid oxidation of NO• and are consumed
through dietary sources (Figure 1B). Indeed, several mammalian
enzymes have been reported to reduce inorganic nitrate and/or
nitrite leading to the generation of NO•, including xanthine oxi-
doreductase (XOR), mitochondrial aldehyde oxidase, and cyto-
chrome P450 (Godber et al., 2000; Kozlov et al., 2003; Li et al.,
2008). In addition, nitrite reductase activities have also been
reported to be exhibited by deoxyhemoglobin in blood and deox-
ymyoglobin in cardiac muscle (Cosby et al., 2003; Shiva et al.,
2007). Therefore, such enzymes may act to ensure an adequate
supply of bioactive NO• under conditions, where the activity of
NOS enzymes becomes impaired.
NO• and its impact on protein and cellular function
There is growing recognition that NO• and other nitrogen-
containing free radicals derived from it can act as key signalling
effectors. For example, NO• has been identified as a ligand of
the soluble guanylyl cyclase, which in turn stimulates the pro-
duction of cyclic guanosine monophosphate, a key second
messenger implicated in the activation of protein kinase G
(McDonald and Murad, 1996). Moreover, NO• can also alter the
activity of proteins by promoting various post-translational mod-
ifications. Firstly, NO• has been shown to induce S-nitrosylation
of cysteine thiol groups (in the presence of an electron acceptor
to form S–NO bonds) in a variety of proteins including Parkin,
Bcl-2, and caspase-3, thereby leading to changes in cell growth
capacity, mitochondrial function, and cell survival (Mannick
et al., 2001; Azad et al., 2006; Sunico et al., 2013). Indeed, dif-
ferent mechanisms of nitrosylation have been described, includ-
ing trans-nitrosylation by small molecular weight NO• carriers,
such as S-nitrosoglutathione, as well as metalloprotein-catalyzed
S-nitrosylation (Gaston et al., 2003; Doulias et al., 2010;
Evangelista et al., 2013). Conversely, S-nitrothiols can be
degraded by various enzymes including the S-nitroglutathione
reductase and thioredoxin systems, which can confer protection
against nitrosative stress (Benhar et al., 2009). It is important to
highlight the distinction between nitrosylation, which is defined
as the direct addition of NO• to a reactant, and nitrosation,
which refers to the addition of a nitrosonium ion (NO+) to a
nucleophilic group, such as a thiolate. There is increasing evi-
dence that now supports protein nitrosation as an important
mechanism in the regulation of cellular function and disease
pathology, including the development of cardiovascular and neu-
rodegenerative disorders (Soetkamp et al., 2014; Seneviratne
et al., 2016). In addition to S-nitrosylation and nitrosation, the
process of nitration, i.e. the incorporation of a nitro group (–NO2)
into amino acid residues, has similarly been reported to convey
marked structural and/or functional alterations in proteins such
Figure 1 NO• production and its involvement in disease pathogen-
esis. (A) Schematic diagram illustrating the involvement of
increased production of NO• and associated RNS (e.g. ONOO–) in
the development of various pathologies. (B) NO• biosynthesis is
predominantly catalyzed by three isoforms of NOS that exhibit dis-
tinct activation mechanisms and tissue distributions: namely nNOS,
iNOS, and eNOS. All three NOS isoforms use L-arginine as a sub-
strate, which is converted into NO• and citrulline, and oxygen and
NADPH as co-factors. The enzymes nNOS and eNOS are constitu-
tively expressed in mammalian cells and synthesize NO• in response
to elevated intracellular calcium by increasing calmodulin (Cmdn)
binding to NOS, although they may also be activated or inhibited
through their phosphorylation by upstream protein kinases. In con-
trast, iNOS protein is either very low or undetectable in most cell
types; however, stimulation with, for example, cytokines or endo-
toxins, can lead to increased iNOS gene transcription, resulting in
enhanced production of NO• in certain cell types (e.g. immune
cells). Alternatively, NO• can also be generated by the enzyme-
mediated reduction of NO3
– and NO2
–, anions derived from the oxi-
dation of NO• or through dietary sources, as indicated. CYP450,
cytochrome P450. The plus sign (+) denotes a stimulatory effect.
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as the molecular chaperones heat shock protein 60 (HSP60)
and HSP90 (Franco et al., 2015; Campanella et al., 2016).
Notably, further NO•-mediated alterations to protein function
can occur through the formation of derived RNS such as peroxy-
nitrite (ONOO–), a highly reactive anion generated by the reaction
of NO• with the superoxide anion. Indeed, the accumulation of
peroxynitrite has been shown to promote post-translational modi-
fications including protein nitration or thiol oxidation (Quijano
et al., 1997) and perturb cellular function by inducing lipid peroxi-
dation (Radi et al., 1991) or through its damaging effects on DNA
and mitochondrial integrity (Radi et al., 2002; Radovits et al.,
2007). Therefore, signalling mediated through NO• has been
shown to impact on protein and cellular function in a number of
different ways.
The ECS
The ECS is a ubiquitous ligand-directed signalling system,
which has been implicated in regulating a wide range of physi-
ological processes and pathologies, including energy homoeo-
stasis, cardiovascular disease, cancer, and neurodegeneration
(Di Marzo and Petrocellis, 2006; Mukhopadhyay et al., 2010b;
Oddi et al., 2012). Two key lipid-derived molecules that act as
endogenous ligands for this system are anandamide (N-arachi-
donoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG)—
commonly referred to as endocannabinoids. Both AEA and 2-AG
can be synthesized on demand within the plasma membrane
from arachidonic acid-derived lipids (Basavarajappa, 2007;
Alger and Kim, 2011) (Figure 2A). AEA generation from its mem-
brane phospholipid precursor N-acylphosphatidylethanolamine
(NAPE) is driven by the action of the enzyme NAPE-hydrolyzing
phospholipase D (NAPE-PLD) (Okamoto et al., 2004). In con-
trast, phospholipase C (PLC)-mediated cleavage of membrane
phosphatidylinositols gives rise to a diacylglycerol (DAG) precursor
whose subsequent hydrolysis (via DAG lipase activity) permits the
formation of 2-AG (Ueda et al., 2011). In addition to these syn-
thetic pathways, enzymes that catalyze the degradation of AEA
and 2-AG have also been characterized, including fatty acid
amide hydroxylase (FAAH) and monoacylglycerol lipase (MAGL),
respectively (Taschler et al., 2011). Furthermore, several oxidative
enzymes, including lipoxygenases, cytochrome P450 monooxy-
genases, and cyclooxygenase-2 (COX-2), can metabolize endocan-
nabinoids into bioactive derivatives such as eicosanoids, which
may function to mediate some of the biological actions of endo-
cannabinoids (Almada et al., 2015; Urquhart et al., 2015; Zelasko
et al., 2015).
Both AEA and 2-AG evoke cellular and physiological responses
through binding to and activating two distinct G protein-coupled
receptors identified as the cannabinoid type 1 (CB1R) and type 2
(CB2R) receptors (Matsuda et al., 1990; Munro et al., 1993).
Various synthetic CB1R and/or CB2R agonists (e.g. CP 55,940,
ACEA, WIN 55,212-2, JWH-133, and HU-210) have been used to
provide mechanistic insight into the regulation of energy homoeo-
stasis by the ECS (Table 1) (Mechoulam et al., 1995; South and
Huang, 2008; Deveaux et al., 2009; Lipina et al., 2010; O’Hare
et al., 2011). Importantly, these are often applied in combination
with selective receptor antagonists to determine receptor-specific
responses. Such cannabinoid receptor blockers act by competitively
binding and preventing activation of a receptor by an agonist
(i.e. as an antagonist) and/or function as inverse agonists
through supressing spontaneous (ligand-free) receptor signal-
ling. For example, SR141716 (also known as rimonabant) has
been shown to act as both CB1R antagonist and inverse agonist
(Bouaboula et al., 1995; Landsman et al., 1997). Notably, endo-
cannabinoids have also been reported to mediate some of their
biological effects through alternative molecular targets such as
the orphan G protein-coupled receptor GPR55, the cation channel
transient receptor potential cation channel subfamily V member 1
(TRPV1), and the peroxisome proliferator-activated receptor
(PPAR) α and γ isoforms (O’Sullivan, 2007; Miyashita et al., 2012;
Sharir et al., 2012).
Modulation of nitrergic signalling by the ECS
Growing evidence indicates that ECS ligands are able to regu-
late the formation and/or release of NO• and derived RNS, in an
either positive or negative manner depending upon cell type
and stimulus, by acting on distinct molecular targets (Figure 2B
and Table 2). In the following sections, we discuss the role of
these ECS modulators in regulating NO• formation via CB1R,
CB2R, and/or alternative molecular targets.
CB1R-mediated regulation of NO• signalling
Several independent studies provide evidence that CB1R acti-
vation can act to suppress NO• synthesis. For example, Molina-
Holgado et al. (1997) demonstrated that LPS-induced release of
NO• in primary mouse astrocytes is attenuated by AEA and the
synthetic cannabinoid agonist CP 55,940 in a CB1R-dependent
manner. Notably, this response coincided with the ability of
these cannabinoid ligands to negate LPS-induced iNOS expres-
sion (mRNA and protein). Moreover, NO• production by iNOS in
response to inflammatory stimuli has similarly been shown to
be suppressed following CB1R activation in saphenous vein
endothelial cells (Stefano et al., 1998), microglial cells
(Waksman et al., 1999; Cabral et al., 2001), and neurons
(Esposito et al., 2002; Molina-Holgado et al., 2002; Sheng et al.,
2005; Fernandez-Lopez et al., 2006; Ribeiro et al., 2013).
Notably, it has been suggested that in microglia, the ability of AEA
to suppress iNOS activation may be mediated, at least in part,
through CB1R-induced activation of MAPK phosphatase-1 (MKP-1),
a proposed negative regulator of iNOS (Wang et al., 2009;
Krishnan and Chatterjee, 2015). It is noteworthy that these sup-
pressive effects of CB1R signalling upon NOS activity are not
restricted to the iNOS isotype. For example, the CB1R agonists
WIN 55,212-2, CP 55,940, and HU-210 have also been reported to
inhibit KCl-induced activation of nNOS in cerebellar granule cells
(CGCs) (Hillard et al., 1999). Importantly, this impaired activation
of nNOS in response to CB1R stimulation in CGCs coincided with
reduced influx of calcium through voltage-operated calcium channels
following membrane depolarization (Hillard et al., 1999). Consistent
with these findings, mice deficient for CB1R exhibit increased
total NOS activity in the cerebral cortex (subventricular zone)
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Figure 2 Major pathways involved in the biosynthesis of endocannabinoids and the modulation of NO• production by the ECS. (A)
Schematic showing the principal enzymes implicated in the synthesis of the endocannabinoids AEA and 2-AG, which in turn can act on target
receptors such as CB1R and/or CB2R in order to convey their biological actions. (B) Activation of CB1R and/or CB2R has been reported to
either stimulate or repress the activity of enzymes implicated in NO• synthesis as indicated (i). Cannabinoid receptor activation can lead to
either the activation or impairment of intracellular cAMP levels depending on cell type, which in turn may accentuate or relieve PKA-
mediated inhibition of NOS-generating enzymes, respectively (ii). Alternatively, CB1R stimulation has been reported to repress NOS activity
through activating the protein phosphatase MKP-1 (iii). Endocannabinoids such as AEA have also been shown to target the vanilloid recep-
tor TRPV1 and voltage-activated calcium channels (VACCs) (iv). In these cases, TRPV1/VACC activation would promote elevations in intracel-
lular calcium signalling that may subsequently impact upon the activity of NOS enzymes, for example by regulating CAMKII activity and/or
calmodulin binding. Following their uptake into cells, endocannabinoids can also be further processed (by the action of COX enzymes) into
derived metabolites such as prostaglandins (eicosanoids), which have also been shown to modulate NOS activity (v).
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compared to wild-type counterparts, concomitant with reduced
neurogenesis in the denate gyrus and subventricular zone (Kim
et al., 2006). Notably, this impaired neurogenesis observed in
CB1R-deficient mice was reversed following administration of
the nNOS-preferring inhibitor 7-nitroindazole. In addition, inde-
pendent work by Nozaki and colleagues revealed that mechan-
ical allodynia and neuronal activation of the trigeminal nucleus
induced by the NO• donor nitroglycerin were completely abol-
ished in mice deficient for FAAH, the main enzyme responsible
for degrading AEA (Kim et al., 2006). Notably, the nitroglycerin-
induced effects were found to be restored in the FAAH knockout
mice following inhibition of CB1R by SR141716 (Kim et al.,
2006).
In contrast to the repressive effects of ECS activation upon
NO• formation, evidence exists to suggest that ECS stimulation
may act to increase NO• levels under certain conditions and/or
in specific cell types. For example, AEA has been reported to
stimulate NO• generation and/or release in human monocytes
(Stefano et al., 1996), rat median eminence fragments (Prevot
et al., 1998), human saphenous vein segments (Stefano et al.,
1998), and cultured human endothelial cells (Stefano et al.,
1998; Fimiani et al., 1999; Mombouli and Vanhoutte, 1999). In
the study by Prevot et al. (1998), increased NO• production in
rat median eminence fragments in response to AEA stimulation
was found to be dependent upon CB1R activity. Moreover, 2-AG
treatment has been shown to induce an immunosuppressive
response in human monocytes and immunocytes from Mytilus
edulis coinciding with a CB1R-mediated increase in NO• release
(Stefano et al. 2000). In a separate study by Carney et al.
(2009), stimulation of CB1R by the cannabinoid receptor ago-
nists CP 55,940 and WIN 55,212-2 elevated NO• production via
nNOS in N18TG2 neuroblastoma cells. CB1R-induced NO•
Table 1 Synthetic modulators of cannabinoid receptor function.
Name Activity at CB1 (Ki in nM) Activity at CB2 (Ki in nM) Comments References
ACEA 1.4 ± 0.3 >2000 Selective CB1 receptor agonist Lipina et al. (2010), Tedesco et al. (2010)
AM251 7.5 2000–3000 Selective CB1 receptor antagonist/inverse agonist Eckardt et al. (2009)
SR141716 1.8 ± 0.2 – Selective CB1 receptor antagonist/inverse agonist Jbilo et al. (2005), Huang et al. (2010)
JWH-133 680 3.4 Selective CB2 receptor agonist Li et al. (2013)
AM-630 5.2 × 103 31.2 Selective CB2 receptor antagonist/ inverse agonist Deveaux et al. (2009)
CP 55,940 0.5 ± 0.1 2.8 ± 0.4 Non-selective potent CB1/2 receptor agonist South and Huang (2008)
HU-210 0.1–0.7 0.2–0.5 Non-selective potent CB1/2 receptor agonist Athanasiou et al. (2007)
WIN 55,212-2 4.4 ± 1.3 1.2 ± 0.25 Non-selective CB1/2 receptor agonist Gustafsson et al. (2006)
Citations refer to studies performed using the compounds listed in order to elucidate the functional role of CB1R and/or CB2R.
Table 2 Effects of ECS modulation upon NO• production in different cell types and tissues.
Cell type/tissue Receptor/target
mediating response
NO• production and/or
release (↑/↓)
Specific NOS isoform(s)
implicated (if known)
References
Human saphenous vein
endothelial cells
CB1R ↓ iNOS Stefano et al. (1998)
Microglial cells CB1R ↓ iNOS Waksman et al. (1999), Cabral et al. (2001)
C6 cells CB1R ↓ iNOS Esposito et al. (2006)
CGCs CB1R ↓ nNOS Hillard et al. (1999)
Neurons CB1R and/or CB2R ↓ ? Molina-Holgado et al. (2002), Ribeiro et al. (2013)
Rat placenta CB1R and CB2R ↓ ? Cella et al. (2008)
Rat medullary thick ascending
limb suspensions
CB1R ↑ ? Silva et al. (2013)
Rat median eminence CB1R ↑ ? Prevot et al. (1998)
Human monocytes CB1R ↑ ? Stefano et al. (2000)
N18TG2 neuroblastoma cells CB1R ↑ nNOS Carney et al. (2009)
Gastric tissue CB1R ↑ ? Rutkowska and Fereniec-Golebiewska (2009)
Kidney (mouse) CB1R ↑ iNOS Mukhopadhyay et al. (2010a)
Heart tissue (mouse) CB1R ↑ ? Mukhopadhyay et al. (2010b)
Kidney (mouse) CB2R ↓ iNOS Mukhopadhyay et al. (2010c)
Macrophages CB2R ↓ ? Ross et al. (2000)
Rat precerebellar neurons CB2R ↓ iNOS Oddi et al. (2012)
Rat heart CB2R ↓ iNOS Gonzalez et al. (2011)
Rat precerebellar neurons CB2R ↑ nNOS Oddi et al. (2012)
Neonatal cardiac cells CB2R ↑ iNOS Shmist et al. (2006)
Rat heart CB2R ↑ eNOS Gonzalez et al. (2011)
Isolated rat mesenteric arterial
bed
TRPV1 ↑ ? Poblete et al. (2005)
Rat placenta TRPV1 ↑ ? Cella et al. (2008)
The table outlines the reported effects of CB1R, CB2R, or TRPV1 activation upon NO• production and/or release in the cell types/tissues listed. The involvement of the dif-
ferent ECS components (i.e. CB1R, CB2R, or TRPV1) is inferred from the use of selective agonists and/or through their genetic or pharmacological inhibition in the studies
cited. Also included are details regarding the specific NOS isoform(s) involved if known. Arrows indicate increased (↑) or repressed (↓) NO• production as evidenced/
inferred by changes in NO• levels, effects of NOS inhibition, altered NOS expression, and/or nitrosative stress.
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production has also been implicated in mediating the ability of
ACEA to protect against aspirin-induced gastric ulceration in rats
(Rutkowska and Fereniec-Golebiewska, 2009). Consistent with
these findings, doxorubicin-induced oxidative/nitrosative stress
has also been reported to be mitigated in the hearts of CB1R
knockout mice (Mukhopadhyay et al., 2010c). Therefore, CB1R
can act to positively or negatively modulate NO• production
depending on cell/tissue type and context.
Regulation of nitrergic signalling by CB2R
Several studies have also implicated a role for CB2R in the
modulation of NO• production and/or release. For example,
CB2R agonist treatment has been reported to attenuate
cisplatin-induced iNOS expression and nitrosative stress in
mouse kidneys (Mukhopadhyay et al., 2010a). In accord with
this, inhibition of LPS-induced NO• release in macrophages by
WIN 55,212-2 was shown to be mediated through stimulation of
CB2R (Ross et al., 2000). Interestingly, independent work by
Oddi et al. (2012) revealed that daily treatment of rats with the
CB2R agonist JWH-015 for one week markedly attenuated hemi-
cerebellectomy induction of iNOS expression and associated oxi-
dative/nitrosative stress, concomitant with improved neurological
outcome measures. Intriguingly, Oddi et al. (2012) further demon-
strated that JWH-015 treatment increased nNOS expression and
activity in axotomized neurons, and the observed neuroprotection
conveyed by CB2R activity was abrogated in response to pharma-
cological inhibition of nNOS.
Conversely, the naturally occurring cannabinoid compound
delta-9-tetrahydrocannabinol (Δ9-THC) has been reported to
increase NO• production in neonatal cardiac cells through the
induction of iNOS activity in a CB2R-dependent manner, thereby
protecting cardiac cells from hypoxic damage (Shmist et al.,
2006). Notably, the NOS inhibitor Nω-Nitro-L-arginine methyl
ester (L-NAME) was found to block this Δ9-THC-induced cardio-
protective action (Shmist et al., 2006). In accord with this,
administration of the cannabinoid receptor agonist WIN 55,212-2
has also been shown to improve cardiac recovery following
ischaemia/reperfusion (I/R) injury in the hearts from Zucker dia-
betic fatty rats by restoring coronary perfusion pressure and heart
rate to pre-ischaemic levels (Gonzalez et al., 2011). Importantly,
this cardioprotective action concurred with a reduction in cardiac
iNOS expression whilst increasing eNOS expression in diabetic
hearts subject to I/R injury. Moreover, the WIN 55,212-2-mediated
cardiac recovery was completely blocked by the CB2R antagonist
AM-630, thereby indicating a key cardioprotective role for this
receptor (Gonzalez et al., 2011).
Although it remains unclear why CB1R/CB2R stimulation
should convey such disparate actions upon nitrergic signalling
(i.e. positive or negative regulation of NO• production) in distinct
cell/tissue types or in response to different stimuli, this may be
due to the differential modulation of pathways that have been
implicated in NO• production. For example, CB1R activation has
been shown to either promote the accumulation or impair pro-
duction of intracellular cAMP in different cell types, which in turn
may accentuate or relieve protein kinase A (PKA)-mediated
inhibition of NOS-generating enzymes, respectively (Glass and
Felder, 1997; Hampson and Grimaldi, 2001). Alternatively, it is
possible that tissue-selective expression of specific NOS iso-
forms may also impact upon ECS modulated NO• production,
whereby the extent of coupling of ECS signalling to the activa-
tion of certain NOS isotypes may be more prominent in certain
cell types.
Alternative targets involved in the modulation
of NO• production
ECS ligands may also promote their biological actions by
binding to alternative molecular targets, including the non-
selective cation channel TRPV1 (Miyashita et al., 2012). For
example, AEA has been reported to modulate NO• levels in rat
placenta by two independent mechanisms, either by decreasing
NOS activity through stimulation of CB1R/CB2R, or alternatively,
by upregulating NO• formation via TRPV1 activation (Cella et al.,
2008). In addition, both AEA and the TRPV1 agonist capsaicin
have been shown to stimulate NO• release in the isolated rat
mesenteric arterial bed, with their stimulatory effects being atte-
nuated following co-incubation with TRPV1 antagonists (Poblete
et al., 2005). Moreover, a separate study by Luce et al. (2014)
demonstrated the ability of AEA to decrease oxytocin and vaso-
pressin secretion from neurohypophysis in adult rats. Notably,
the inhibitory actions of AEA were found to be negated using
the NOS inhibitor L-NAME, as well as CB2R and TRPV1 antago-
nists (Luce et al., 2014). These findings reveal a potential link
between endocannabinoid, NO•, and oxytocin/vasopressin-
induced signalling, which may serve to modulate homoeostatic,
behavioural, and reproductive processes (Luce et al., 2014).
Furthermore, it is possible that modulation of NO• production
and associated nitrergic signalling may be mediated through the
reported ability of ECS ligands to activate PPAR isoforms
(O’Sullivan, 2007; Prakash et al., 2015), although no direct evi-
dence for this has yet been obtained. Alternatively, metabolites
derived from endocannabinoids, such as prostaglandins, may
also participate in the modulation of NO• formation by the ECS
(Urquhart et al., 2015). For example, the polyunsaturated
omega-6 fatty acid arachidonic acid (C20:4n-6) produced follow-
ing AEA degradation by FAAH serves as a substrate for cyclooxy-
genases, which in turn catalyze the formation of prostaglandins.
Notably, evidence from several studies indicates that prosta-
glandins can stimulate or inhibit NOS activity, depending on cell
type and context (Milano et al., 1995; Ribeiro et al., 2004; Cella
et al., 2006). However, whether endogenous ECS ligands can
modulate NOS activity via the action of prostaglandins and/or
other derived metabolites remains unknown.
Nitrergic modulation of ECS function
It is important to highlight that in addition to the growing body
of evidence implicating a regulatory role for the ECS in modulating
NO• production and associated nitrergic signalling, there are also
several studies suggesting that RNS may act to alter ECS function.
For example, a study by Kokkola et al. (2005) using [35S]-GTPγS
autoradiography and membrane binding assays revealed that
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treatment with the NO• donor S-nitroglutathione (GSNO) led
to the inhibition of CP 55,940 and WIN 55,212-2-induced CB1R
signalling in the cerebral cortex, hippocampus, and the globus
pallidus regions of rat brain. It is plausible that the inhibitory
action of GSNO may be due to NO•-induced post-translation
modifications of the CB1 receptor, a possibility that would
require further analysis. In addition to the reported effects on
CB1R function, work by Hervera et al. (2010) has also implicated
nNOS-derived NO• in the regulation of CB2R gene transcription
during neuropathic pain, whereby sciatic nerve injury was
shown to increase CB2R mRNA abundance in spinal cords of
wild-type and iNOS-KO mice relative to naive (control) mice, but
not in nNOS-deficient animals. In a separate study, rats adminis-
tered with the NO• donor nitroglycerin were found to exhibit
increased heart tissue content of the endocannabinoid 2-AG
(Wagner et al., 2006). Notably, this elevation in cardiac 2-AG
abundance coincided with nitroglycerin-mediated protection
against myocardial infarction, an effect shown to be dependent
upon CB1R activity. Allied to this, administering 2-AG or its
metabolically stable derivative noladinether before I/R mim-
icked the cardioprotective effects of nitroglycerin and similarly
reduced infarct size (Wagner et al., 2006).
In addition, a study performed in isolated bovine brain micro-
vessels, an ex vivo model of the blood–brain barrier, revealed
that stimulation of CB1R enhances the activity of AMT, a select-
ive AEA membrane transporter protein, by increasing NOS activ-
ity and NO• production (Maccarrone et al., 2006). In the same
study, AMT activity was shown to be reduced following CB2R
stimulation, concomitant with suppressed NOS activity and NO•
release. Allied to this, immunoimaging revealed that different
endothelial cells vary in the expression of CB1R and CB2R on their
luminal and/or abluminal sides (Maccarrone et al., 2006). Such
differential localization of cannabinoid receptors may facilitate
coordinated AMT activity on the luminal and abluminal mem-
branes, thereby promoting directional transport of AEA through
the blood–brain barrier and other endothelial cells (Maccarrone
et al., 2006). Collectively, these findings indicate that elevated
levels of RNS may influence ECS function by altering the expres-
sion, activity, and/or localization of its key components.
ECS–NO• crosstalk in disease development and treatment
Given the reported involvement of the ECS and NO• signalling
in the modulation of cellular function and the development of
various physiopathological processes, it is likely that crosstalk
between these signalling systems may contribute to nitrosative
stress-related disease initiation and/or progression. These
potential links are discussed in the following sections and sum-
marized in Figure 3.
Involvement of ECS–NO• crosstalk in disorders of the central
nervous system
Regarding pathologies of the central nervous system (CNS),
ligand-induced activation of CB1R and/or CB2R has been
reported to convey either cytotoxic or cytoprotective actions in
neurons and astrocytes, depending on cell stimulus, through
altered NO• production (Molina-Holgado et al., 2002; Duncan
and Heales, 2005; Esposito et al., 2006; Shmist et al., 2006;
Carney et al., 2009; Oddi et al., 2012; Aguirre-Rueda et al.,
2015). Notably, elevated levels of AEA in the brain in response
to FAAH inhibition have been associated with enhanced neur-
onal survival and reduced neurodegeneration in a mouse model
of traumatic brain injury, coinciding with a reduction in the num-
ber of iNOS-expressing (activated) microglia in the ipsilateral cor-
tex (Tchantchou et al., 2014). Furthermore, Gomez-Galvez et al.
(2016) demonstrated that stimulation of CB2R in mice adminis-
tered with HU-308 led to reduced inflammation in the striatum of
LPS-lesioned mice, concomitant with the attenuation of LPS-
induced iNOS gene expression. Notably, these findings are in
agreement with the reported ability of CB2R activation to inhibit
NO• production in RAW264.7 macrophages (Ross et al., 2000).
Evidence also exists showing that activation of CB1R in CA1
pyramidal neurons impairs dendritic integration of excitatory
inputs and spatial memory formation through stimulation of
hyperpolarization-activated cyclic nucleotide-gated channels
that underlie the H-current (Maroso et al., 2016). In this case,
the latter has been reported to function as a key modulator of
dendritic excitability that relies upon NOS-driven NO• formation
(Maroso et al., 2016). Independent work by Prevot et al. (1998)
also demonstrated that CB1R activation by AEA can stimulate
NO• release from endothelial cells of median eminence frag-
ments in rats, thereby promoting enhanced secretion of
gonadotropin-releasing hormone (GnRH), a neurohormone that
plays a pivotal role in controlling reproductive function.
Furthermore, work by Esposito et al. (2006) revealed that CB1R
stimulation counters increased iNOS protein and NO• production
in β amyloid-stimulated rat C6 glioma cells. Notably, this CB1R-
mediated response coincided with inhibition of NO•-dependent
hyperphosphorylation of tau, a microtubule-associated protein
implicated in neurofibrillary tangle formation and the develop-
ment of Alzheimer’s disease, in co-cultured PC12 neurons
(Esposito et al., 2006). Collectively, these studies provide emer-
ging evidence supporting an important role for the ECS–NO• sig-
nalling axis in controlling the physiological actions and/or
viability of key cellular components of the CNS (i.e. neurons,
astrocytes, microglia, brain microvascular endothelial cells),
thereby impacting on cognitive and neuroendocrine function, as
well as implicating the ECS–NO• pathway as a potential thera-
peutic target to alleviate neurodegeneration in response to
brain injury and neurological conditions such as Parkinson’s dis-
ease, vascular dementia, and Alzheimer’s disease (Koppel et al.,
2014; Aso et al., 2016; Austin and Katusic, 2016; Gomez-Galvez
et al., 2016; Jayant and Sharma, 2016).
Modulation of pathological changes in peripheral tissues and
organs by ECS–NO• signalling
ECS and NO•-dependent signalling has also been shown to
modulate the physiology of various other organ systems, includ-
ing the cardiovascular and renal systems and those implicated
in the regulation of energy homoeostasis (Nisoli et al., 2004; Batkai
et al., 2007a; Tedesco et al., 2008; Mukhopadhyay et al., 2010a;
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Gonzalez et al., 2011). For example, genetic deletion and
pharmacological inhibition of CB1R has been reported to miti-
gate cisplatin-induced inflammation and cell death in mouse
kidneys, concomitant with improvements in renal function (as
evidenced by the attenuation of elevated creatinine and serum
blood urea nitrogen levels) (Mukhopadhyay et al., 2010a).
Notably, this reported ability of CB1R blockade to alleviate renal
dysfunction was associated with the diminution of iNOS expres-
sion and nitrotyrosine levels in the kidney following cisplatin
treatment (Mukhopadhyay et al., 2010a). In a separate study by
Silva et al. (2013), CB1R stimulation was shown to reduce oxy-
gen consumption, a key determinant of active sodium chloride
reabsorption, in rat medullary thick ascending limb suspensions,
concomitant with increased NO• production. Furthermore, AEA
has also been reported to induce vasodilatation of afferent
arterioles of the kidney by increasing endothelial release of NO•
(Deutsch et al., 1997).
NO•-dependent signalling may also underlie, at least in part,
some of the metabolic responses conveyed by altered ECS activ-
ity. For example, the CB1R agonist ACEA has been reported to
reduce eNOS expression in white adipocytes, concomitant with
a reduction in mitochondrial biogenesis (Tedesco et al., 2010).
Consistent with this, genetic and pharmacological inhibition of
CB1R has been associated with the induction of eNOS-
dependent mitochondrial biogenesis in adipocytes (driven by
increased eNOS mRNA and protein abundance), coinciding with
enhanced activation of AMP-activated protein kinase, a key
positive regulator of fatty acid oxidation, in cultured adipocytes
and white adipose tissue of high fat-fed mice (Tedesco et al.,
2008). Furthermore, it is possible that CB1R inhibition may fur-
ther stimulate eNOS by enhancing the activity of protein kinase
B (PKB, also known as Akt), which has been identified as a posi-
tive modulator of eNOS function by phosphorylating its Ser617
and Ser1177 residues (Dimmeler et al., 1999; Fulton et al.,
1999; Michell et al., 2002). In accord with this, CB1R stimulation
or blockade has been associated with increased or reduced
PKB/Akt activity, respectively (Esposito et al., 2008; Eckardt
et al., 2009; Lipina et al., 2016). However, such a link between
CB1R-regulated PKB/Akt signalling and eNOS activity has not yet
been established. Interestingly, AEA has been shown to increase
insulin-stimulated glucose uptake in differentiated 3T3-L1 adipo-
cytes through a CB1R-dependent mechanism involving NOS activ-
ity; however, the involvement of PKB/Akt was not determined in
this study (Gasperi et al., 2007). Given the fact that NO• has
been implicated in the regulation of insulin sensitivity and insulin
secretion, as well as other key metabolic processes including glu-
cose utilization, lipogenesis, and inflammation (Henningsson
et al., 2002; Nakata and Yada, 2003; Razny et al., 2011; Trevellin
et al., 2014; Li et al., 2016), further work will required to deter-
mine the extent to which NO•-dependent signalling contributes
towards ECS-induced regulation of such pathways that impact
upon energy homoeostasis and metabolism (Cinar et al., 2014;
Gonzalez-Mariscal et al., 2016; Lipina et al., 2016).
It is possible that ECS–NO•-regulated metabolic responses
may also contribute to the development and/or attenuation of
related pathological conditions including non-alcoholic fatty
Figure 3 Involvement of the ECS–NO• signalling axis in disease development and/or treatment. Schematic outlines the reported involve-
ment of ECS–NO• signalling in the tissues/processes presented. The participation of different ECS components (i.e. CB1R, CB2R, or TRPV1)
is inferred from the use of selective agonists and/or through genetic or pharmacological inhibition, and is presented in brackets if known. Also
included are details of the specific NOS isoform(s) involved in mediating the indicated response if determined. Arrows denote an inferred induc-
tion (↑) or repression/alleviation (↓) of the indicated process/pathology in response to activation of the specified ECS component.
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liver disease (NAFLD) and cardiac dysfunction (Gonzalez et al.,
2011; Jorgacevic et al., 2015; Nozaki et al., 2015). For example,
CB1R inhibition by SR141716 has been reported to improve
hepatic oxidative/nitrosative stress in mice with NAFLD induced
by high fat feeding (Jorgacevic et al., 2015). The work of
Gonzalez et al. (2011) also revealed that CB2R activation serves
to mitigate cardiac I/R injury in Zucker diabetic rats by restoring
cardiac iNOS/eNOS equilibrium (by decreasing or increasing car-
diac iNOS and eNOS expression, respectively). Cardioprotection
has also been reported to be conveyed by the NO• donor nitro-
glycerin, as evidenced by its ability to mitigate myocardial
infarction in rats through stimulation of CB1R activity in
response to increased 2-AG levels in the heart (Wagner et al.,
2006). Therefore, reciprocal regulation of ECS and NO•-induced
signalling may play a pivotal role in controlling cardiomyocyte
function and/or viability. In addition to these cardioprotective
actions, ligand-induced activation of CB1R and CB2R has also
been documented to attenuate hypertrophy of neonatal rat car-
diomyocytes by a mechanism involving eNOS activity (Lu et al.,
2014). Recent work by Stanley et al. (2016) also demonstrated
the ability of AEA to promote endothelium-dependent vasore-
laxation in human mesenteric arteries via a CB1R and NO•-
dependent pathway. Therefore, these studies highlight the dif-
ferent ways that ECS–NO• signalling axis can impact upon car-
diovascular function.
Importantly, however, the extent to which altered ECS func-
tion, such as that observed in response to obesity or ageing
(Batkai et al., 2007b; Lipina et al., 2016), contributes to
pathology-driven changes in NO• signalling, particularly in vivo,
remains poorly understood. Further work utilizing relevant
mouse models of NOS deficiency, for example, may provide a
better understanding of the role that NO•-dependent signalling
plays in mediating ECS-induced changes in the function of the
CNS and extraneural tissue systems. To this end, combined
therapeutic targeting of ECS components and NOS isoforms may
provide a more effective strategy at preventing and/or treating
certain pathologies. This is exemplified through recent work by
Cinar et al. (2016) reporting the ability of a hybrid inhibitor of
peripheral CB1R and iNOS to mitigate liver fibrosis induced by
CCl4 or bile duct ligation in mice. Notably, Cinar et al. (2016)
demonstrated that the hybrid CB1R/iNOS antagonist surpassed
the antifibrotic efficacy of the CB1R antagonist SR141716 or the
iNOS inhibitor 1400W. Subsequent work utilizing a similar
approach by dual targeting of the ECS and NO• systems may
reveal further alterations to physiological and/or pathological
responses in the liver (e.g. steatosis, inflammation) and other
peripheral tissues.
Little is known of how altered ECS function may impact upon
protein modifications mediated by NO• and other RNS leading
to protein nitration, nitrosation, or S-nitrosylation, which have
been implicated in disease pathology (Beckman and Koppenol,
1996; Levonen et al., 2001; Soetkamp et al., 2014; Pereira
et al., 2015; Seneviratne et al., 2016). To this end, further
detailed analysis using mass spectrometry and/or other techni-
ques will be required to establish how the ‘nitro-proteome’ is
influenced by changes in ECS activity, which may also involve
altered enzymatic activity that functions to degrade specific
nitro group modifications including the removal of S-nitrothiols
by S-nitroglutathione reductase. Importantly, such work may
identify novel targets of ECS–NO• signalling that contribute to
disease pathogenesis.
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Conclusion
Collectively, the evidence presented in this review indicates
that ECS activation or inhibition can convey detrimental and/or
beneficial biological actions by altering cellular NO• production
and/or release, depending on cell type and/or stimulus. The
studies highlighted in this review demonstrate that ECS activity
can modulate NO• production and associated downstream pro-
cesses in a number of different ways (Figures 2B and 3).
Moreover, we draw attention to emerging evidence for the recip-
rocal modulation of ECS function by RNS. Crucially, given the
importance of nitrergic signalling and the ECS in the develop-
ment of numerous pathologies (Figure 3), these findings identify
ECS components as potential therapeutic targets for the treat-
ment of nitrosative stress-related neurological, cardiovascular,
and metabolic disorders. Consequently, it will be of great inter-
est to define the molecular targets of ECS–NO• signalling in dis-
tinct tissues under various pathological states and to explore
how ECS-induced nitrergic signalling and/or nitrosative stress
may contribute to alterations in the function(s) of proteins impli-
cated in disease initiation and progression.
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